Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;25(5):409-418.
doi: 10.2174/0113892037269645231031095145.

Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-HER2 scFvs

Affiliations

Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-HER2 scFvs

Foroogh Nejatollahi et al. Curr Protein Pept Sci. 2024.

Abstract

Purpose: We aimed to assess the effects of a cocktail comprising three specific anti- HER2 scFvs on breast tumor formation in a xenograft mouse model and to evaluate quantitative changes in the tumor using stereological analysis.

Methods: Three specific anti-HER2 phage antibodies were produced from a scFv-library using phage display technology. The cell binding capacities of the antibodies were assessed via FACS analysis. Soluble forms of the antibodies were prepared by infecting HB2151-E. coli cells and purified using a centrifugal ultrafiltration method. The purification process was evaluated by SDSPAGE analysis. Two forms of scFv cocktails were prepared, soluble scFv and phage-scFv cocktail, which contained an equal amount/phage of each of the three antibodies. Inbred female BALB/c mice were pretreated with 5 and 20 mg/kg of the soluble scFv cocktail and 1011 phage-scFv cocktail/ kg. The mice were then injected with 2×106 SKBR-3 human breast cancer cells. Total tumor, inflammatory and non-inflammatory volumes were estimated using the Cavalieri principle after preparing photomicrograph slides.

Results: The anti-HER2 scFvs showed significantly higher binding to SKBR-3 cells compared to the isotype control. SDS-PAGE analysis confirmed the high purification of the scFvs. Stereological analysis revealed that the group pretreated with 20 mg/kg of the soluble scFv cocktail exhibited the highest reductions in total tumor volume, non-inflammatory volume, and inflammatory volume, with reductions of 73%, 78%, and 72%, respectively, compared to PBS-pretreated mice (P-value < 0.0001). The volumetric ratio of necrotic tissue to total tumor volume increased by 2.2-fold and 2- fold in the 20 mg/kg of soluble scFv cocktail and phage-scFv cocktail groups, respectively, compared to the PBS-treated mice (P-value < 0.05).

Conclusion: Pre-treatment with a 20 mg/kg anti-HER2 scFv cocktail resulted in a significant reduction in tumor volume and increased necrotic area in a human breast cancer xenograft model, indicating the remarkable anti-tumor effect of the cocktail in vivo.

Keywords: Anti-HER2 scFv cocktail; breast cancer; breast tumor xenograft; necrotic area; stereological analysis; tumor volume..

PubMed Disclaimer

Similar articles

References

    1. Hart V.; Gautrey H.; Kirby J.; Tyson-Capper A.; HER2 splice variants in breast cancer: Investigating their impact on diagnosis and treatment outcomes. Oncotarget 2020,11(46),4338-4357 - DOI - PubMed
    1. Ghauri M.A.; Su Q.; Ullah A.; Wang J.; Sarwar A.; Wu Q.; Zhang D.; Zhang Y.; Sanguinarine impedes metastasis and causes inversion of epithelial to mesenchymal transition in breast cancer. Phytomedicine 2021,84,153500 - DOI - PubMed
    1. Su Q.; Wang J.; Wu Q.; Ullah A.; Ghauri M.A.; Sarwar A.; Chen L.; Liu F.; Zhang Y.; Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer. Phytomedicine 2021,84,153503 - DOI - PubMed
    1. Wu X.; Yang H.; Yu X.; Qin J.J.; Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. Front Pharmacol 2022,13,1012552 - DOI - PubMed
    1. García-Aranda M.; Redondo M.; Immunotherapy: A challenge of breast cancer treatment. Cancers 2019,11(12),1822 - DOI - PubMed